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Digestion-on-a-chip: a continuous-flow modular
microsystem recreating enzymatic digestion in the
gastrointestinal tract†
Pim de Haan, ab Margaryta A. Ianovska, ab Klaus Mathwig, a
Glenn A. A. van Lieshout,c Vassilis Triantis,c
Hans Bouwmeester de and Elisabeth Verpoorte *a
In vitro digestions are essential for determining the bioavailability of compounds, such as nutrients. We
have developed a cell-free, miniaturized enzymatic digestive system, employing three micromixers
connected in series to mimic the digestive functions of the mouth, stomach and small intestine. This sys-
tem continuously processes samples, e.g. containing nutrients, to provide a constant flow of digested mate-
rials which may be presented to a subsequent gut-on-a-chip absorption module, containing living human
intestinal cells. Our system incorporates three-compartment enzymatic digestion, one of the key functions
of the gastrointestinal tract. In each of these compartments, we modify the chemical environment, including
pH, buffer, and mineral composition, to closely mimic the local physiological environment and create
optimal conditions for digestive processes to take place. It will therefore provide an excellent addition to
existing gut-on-a-chip systems, providing the next step in determining the bio-availability of orally adminis-
tered compounds in a fast and continuous-flow ex vivo system. In this paper, we demonstrate enzymatic
digestion in each separate compartment using compounds, starch and casein, as model nutrients. The use
of transparent, microfluidic micromixers based on chaotic advection, which can be probed directly with a
microscope, enabled enzyme kinetics to be monitored from the very start of a reaction. Furthermore, we
have digested lactoferrin in our system, demonstrating complete digestion of this milk protein in much
shorter times than achievable with standard in vitro digestions using batch reactors.
Introduction
Digestion by means of enzymatic reactions is one of several
key functions of the gastrointestinal (GI) tract. The process of
digestion starts immediately upon ingestion, and continues
until the terminal part of the colon. In the oral phase,
ingested materials are first subject to mastication and simul-
taneous mixing with saliva. Starch digestion by amylase, an
enzyme in saliva, starts in this phase at a pH of 6–7. Upon
reaching the stomach, the pH of the ingested material is re-
duced to values as low as 1.0,1 causing the denaturation of
proteins and providing optimal conditions for the enzyme,
pepsin, to work. The gastric mixture is then transferred in
small portions into the duodenum, the first part of the small
intestine. The pH of this mixture is neutralized to 7–8 by a
bicarbonate-rich juice flowing from the pancreas, which also
contains high concentrations of proteases, lipases and other
enzymes aiding the breakdown of nutrients into smaller mol-
ecules. Bile, secreted by the liver and stored in the gall blad-
der, helps to emulsify fats in the mixture, which in this phase
is termed chyme. Smaller molecules (e.g. amino acids, mono-
saccharides) may be transported into the body by active or
passive means by passage through the intestinal epithelium
into the blood or lymph. Any ingested compound (e.g. nutri-
ents, medicinal drugs or toxicants) is subject to the same di-
gestive processes upon oral administration. This process may
have an effect on the amount reaching and eventually
absorbed by the intestinal epithelium, affecting the dose that
reaches the bloodstream, or is bio-available. In order to reach
the systemic circulation, a compound must dissolve from its
matrix, withstand metabolism by digestive juices (enzymatic
action, or acid-catalyzed reactions), and make its way into the
epithelial cell layer. There it must withstand possible intracel-
lular metabolism to move out of the epithelium into the
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blood or lymph, and finally pass through the portal vein sys-
tem in the liver without being metabolized or excreted into
the bile. The term bio-availability, F, is defined as the overall
fraction of a compound which finally reaches the systemic
bloodstream:2
F = FF·FG·FH (1)
In eqn (1), bio-availability is determined by FF, FG and FH.
Bio-accessibility (or pharmaceutical availability3), FF, denotes
the fraction of the dose which is liberated from the matrix,
e.g. a tablet containing the compound of interest, or a toxico-
logical sample, and is not degraded by digestive juices.4 FG is
the fraction which then is able to pass through the gut wall
into intestinal blood vessels, by either actively being taken up
by transporting proteins in the epithelial cells (intracellular
transport), or by passive diffusion through the cell layer (or
paracellular transport). After absorption, compounds will be
transported to the liver through the vena portae, allowing the
liver to process incoming materials before they reach the sys-
temic circulation. The fraction that passes through the liver
without being metabolized is FH. For both medicinal drugs
and toxicants, it is of great importance to understand what
happens to a compound during its entire trajectory through
the GI tract, as this strongly influences the bio-availability of
these compounds.
Most in vitro models of the GI tract to date have focused
on better understanding and quantifying the absorption of
compounds from the intestine over the intestinal wall into
the circulatory system. The sample containing the compounds
of interest is introduced to a barrier model of the human in-
testine. An intestinal barrier model can be any system
containing two compartments separated by a layer
representing the intestinal epithelium. The most commonly
used cell-based system, having the lowest degree of complex-
ity, consists of epithelial cells grown on a Transwell insert in
well plates.5 These Transwell-based systems usually contain
only one cell type (e.g. Caco-2 cells, a human intestinal cancer
cell line), and static medium on either side of the cell layer.
Caco-2 cells can develop an apical and a basolateral side,
showing a polarization pattern analogous to the human intes-
tine. The apical side is in direct contact with the intestinal lu-
men, whereas cells attach to a solid support, e.g. a basal mem-
brane, to form the basolateral side. Samples may be added to
the apical compartment, after which the concentration of the
compound and its metabolites can be determined in the
basolateral compartment, providing information on FG. Sev-
eral different approaches have been developed to miniaturize
and thus improve this type of barrier model of the human in-
testine, leading to so-called gut-on-a-chip devices. Various
modifications have been made to more accurately represent
the in vivo situation in gut-on-a-chip models, such as medium
flow,6 three-dimensional scaffolds,7,8 peristaltic motions and
bacteria,9–12 elements of the immune system,13 combinations
with different organs-on-chips,14–16 and some elements of the
digestive functions.17,18 Also noteworthy are specific devices
to study the pharmacokinetic behavior of medicinal drugs in
the intestine and liver.19–22 However, none of these gut-on-a-
chip systems fully recapitulates enzymatic digestion, a key
function of the gastrointestinal tract which ultimately deter-
mines the bio-availability of ingested compounds.
Common procedures to study the behavior of compounds
in the GI tract involve in vitro digestions, in which the com-
pound of interest is exposed to artificial digestive juices of
varying complexities in a temperature-controlled and stirred
container, having volumes from ten to hundreds of
milliliters.23–26 These in vitro digestions are a tool to study
the bio-accessibility of the compounds, but the methodology
is relatively laborious. Even if performed in a fermenter-like
container, with automated pH control and time-controlled
addition of digestive juices, systems are not autonomous,
and a skilled technician is still required to operate the system
and collect the samples.25,27–29 Miniaturization of such a sys-
tem would allow for automation, as well as a reduced need
for valuable chemicals (such as enzymes) and solvents.
In this report, we describe the design and development of
a miniaturized digestive system, which can be coupled in se-
ries to a gut-on-a-chip to provide a continuous flow of
digested materials (Fig. 1). In this system, samples are con-
tinuously mixed with saliva in the first compartment
(‘mouth’). The output of the mouth is transferred to the next
compartment (‘stomach’), where gastric juice is added. Fi-
nally, the gastric mixture flows to the third compartment
(‘intestine’), where duodenal juice and bile are added. The re-
sult is a solution mixture comparable to chyme, the product
of our digestive system from which compounds are absorbed
Fig. 1 Schematic representation of the cell-free miniaturized digestive system. Samples are introduced at the top left, and are continuously mixed
with artificial digestive juices, in physiologically relevant ratios (as shown by the different flow rates). The digested material, or chyme, is produced
continuously and could be transferred by flow to a subsequent gut-on-a-chip module to study intestinal absorption. Each white circle represents
an inlet pump set to the indicated flow rate.
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in the intestinal tract. Our system will provide information
on FF, and when combined with an absorption model of the
intestine, the combination of FF and FG. Contrary to the com-
monly used batchwise in vitro digestions, our miniaturized
system can be operated in continuous-flow mode, for both
short- and long-term studies. A continuous flow has several
advantages over a batch process, allowing processing of sam-
ples either continuously or in a pulsatile multi-dose regimen.
At the same time, however, we need to very precisely control
the conditions in the three separate compartments. Hence,
solutions entering a compartment must be rapidly mixed
with the relevant digestive juice. Therefore, each “organ” or
compartment of the system consists of a 1.38 μL chaotic
micromixer, based on a microchannel with an array of
herringbone-shaped grooves, formed in the channel ceiling.
These grooves perturb laminar flow profiles, and create two
counter-rotating vortical flows in the channel, thereby folding
the liquids into one another.30 Samples entering each micro-
mixer are continuously mixed with artificial digestive juices
containing enzymes in physiologically relevant ratios. Sam-
ples flow through three consecutive compartments,
representing three digestive processes, to produce a flow of
chyme of 25 μL min−1. This flow rate was chosen for two rea-
sons: 1) the inlet flow rates used (ranging from 1–12 μL
min−1) are low enough to save valuable artificial digestive
juices and samples with respect to larger-scale in vitro diges-
tions, but high enough to maintain steady-state flow condi-
tions by using syringe pumps; and 2) we found in earlier
work that mixing is very fast and efficient at these low flow
rates, occurring within the first section of the micromixer
channels (vide infra for a description of these micromixer
channels containing cycles of herringbone-shaped grooves).31
The ratios of the inlet flow rates (1 + 4 + 8 + 12 μL min−1) in
our system were chosen to approximate the volumetric ratios
of digestive juices in vivo (Fig. 1).27 One of the key strengths
of our system from a chemical point of view is that the condi-
tions in each of the compartments are very different (i.e. min-
eral composition, buffer and pH, enzymes), but enzymatic re-
actions are taking place in all of the compartments.
We have tested the individual compartments of our minia-
turized digestive system with model compounds, to obtain
enzyme kinetic plots to demonstrate enzyme activity in each
stage of our digestion model. This was to make sure that the
enzymes were fully active under the flow transport conditions
inside the microchannels, where they are subjected to shear
stress. Finally, the digestion of a sample containing
lactoferrin, an iron-containing nutritional protein which is
naturally present in milk,32–34 is shown and characterized.
Experimental section
Artificial digestive juices
Artificial saliva, gastric juice, duodenal juice and bile compo-
sitions are given in Table 1. The juices were freshly prepared
on the day of the experiments, according to a modified litera-
ture procedure published by Walczak et al.,27 after optimiza-
tion of the pH of each juice by changing the concentrations
of HCl or NaOH. All chemicals (excluding enzymes) were
dissolved in ultrapure water in volumetric flasks. HCl or
NaOH was then added to adjust the pH of the buffer systems
used for the mouth, stomach and intestine. The pH was veri-
fied with a calibrated pH meter (Metrohm, Herisau, Switzer-
land) at room temperature, and the enzyme content was
added just before adding ultrapure water to the final volume.
This sequence is essential, since the proteins may denature if
added to a solution with a too high or too low pH value. The
juices were warmed to 37 °C in an incubator least 1 h before
the experiment, as described in other studies.25,27 All
chemicals were obtained from Sigma-Aldrich/Merck
(Zwijndrecht, the Netherlands), except sodium dihydrogen
phosphate monohydrate and hydrochloric acid (Acros, Geel,
Belgium), and potassium chloride and sodium chloride
(Duchefa, Haarlem, the Netherlands).
Fabrication of devices
Micromixer devices were fabricated by micromolding
polyĲdimethylsiloxane) (PDMS, Sylgard 184, Dow Corning,
Midland, MI, USA) on SU-8 molds, according to a procedure
we have described in earlier work.31 The 300-μm-wide, 51.5-
mm-long channels contained 16 arrays of cycles of 12
herringbone-shaped grooves each, which greatly enhance
mixing in this laminar-flow regime through chaotic advec-
tion.30,31 The channels were 60 μm deep, and 50 μm deeper
Table 1 Optimized composition of the artificial digestive juices, dissolved























Urea 200 85 100 250
Uric acid 15
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in the groove regions for optimal mixing characteristics.
Channels were sealed off with a glass microscope slide to
yield a hybrid PDMS/glass device. Plateaus (areas with no
grooves before and after each cycle) were incorporated to al-
low for a 300 × 100 μm measurement site, to monitor mixing
and reaction progress (Fig. 2). Each compartment consisted
of a micromixer; and compartments were connected with one
another in series using polyĲtetrafluoroethylene) (PTFE) tub-
ing (0.8/1.6 mm inner/outer diameter, Polyfluor Plastics,
Breda, the Netherlands). Blunt Fine-Ject 21G needles
(HenkeSassWolf, Tuttlingen, Germany) were used to connect
the tubing to syringes.
Enzyme kinetics
The overall function of the enzymes present in the artificial
digestive juices (Fig. 1) is the digestion of food to release nu-
trients. Most biological macromolecules cannot be absorbed
from the intestinal tract in intact form, and have to be hydro-
lyzed to smaller units (monomers or oligomers) before uptake
through the intestinal wall. Polysaccharides such as starch are
cleaved to smaller sugars by amylases in saliva and pancreatic
juice. Proteins are broken down to smaller peptides and sin-
gle amino acids by proteases in the stomach and intestine.
Fats (triglycerides) are hydrolyzed to monoglycerides and free
fatty acids by lipases in the intestine, assisted by bile salts to
emulsify fatty content to achieve better enzyme accessibility.
Enzymatic catalysis greatly enhances the processing rate of
food. For these enzymes, the reaction rate, V, depends on the
substrate concentration, [S], and enzyme parameters Vmax and













In this equation, the reaction rate, V, is equal to the for-
mation of product, P, over time. Vmax is the maximum turn-
over rate of this enzyme under specified conditions, and Km
denotes the concentration of substrate where V = ½ Vmax. This
Michaelis–Menten equation predicts the typical kinetics plot
(V vs. [S]), in which the V curve monotonically increases from
zero and saturates or plateaus at Vmax.
Enzymatic assays – general
Each compartment was decoupled from the rest of the sys-
tem and studied individually to study the enzyme kinetics of
that compartment. Therefore, devices containing a single
micromixer (two inlets, one outlet, as described by Ianovska
et al.31) were used to demonstrate enzymatic function in the
separate compartments. Two syringe pumps (Harvard Appa-
ratus, Pump 11 Pico Plus Elite, Holliston, MA, USA) were
used with glass syringes (250 μL, Kloehn, Whittier, CA, USA)
or plastic syringes (1 mL, Braun, Melsungen, Germany),
containing either the digestive juice or the solution
containing the compound to be digested. Each assay consists
of a labeled model nutrient, which when digested in our sys-
tem causes an increase in fluorescence. Even though the sin-
gle compartments were decoupled from the total system, we
ensured proper functioning of each device by infusing the
digestive juice in one inlet (e.g. gastric juice, in the stom-
ach), and the simulated output of the preceding compart-
ment in the other inlet (e.g. ‘mouth’ output, a mixture of wa-
ter and saliva, at the appropriate ratios, to study the kinetics
in the stomach). The chemical environment inside these
decoupled compartments is therefore the same as in the as-
sembled system. The total flow rate (Qjuice + Qsubstrate) was
2.0 μL min−1 in each separate stage of digestion in these
tests. This lower flow rate was chosen to better be able to
study enzyme kinetics in our system: at 2.0 μL min−1, the
longer residence time of 41.3 s enables us to measure a de-
tectable increase of fluorescence and model the enzyme ki-
netics on-chip.
Enzymatic assays: kinetics of α-amylase in the first stage
(‘mouth’). Artificial saliva was freshly prepared using the
Fig. 2 Diagram of a micromixer channel, containing herringbone-shaped grooves in its surface. Two inlet channels are visible at the left. The
channel is just over 50 mm long, and contains 16 cycles of 12 grooves each. Between cycles, a plateau is incorporated to allow for a 300 × 100 μm
measurement region. At a total flow rate of 2.0 μL min−1, as used in the enzyme kinetics experiments, 51.5 mm channel length corresponds to a
residence time of 41.3 s.
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optimized juice composition (Table 1), containing 11.5
U mL−1 α-amylase in an aqueous mixture of minerals, buff-
ered at pH 6.8, and loaded in one of the syringes. Solutions
with varying concentrations of quenched, fluorescently la-
beled starch (EnzChek Ultra Amylase, ThermoFisher, Wal-
tham, MA, USA) were prepared in ultrapure water. The syrin-
ges were connected to the hybrid PDMS-glass micromixer
using blunt 21G needles and PTFE tubing, with the needle
directly inserted into a punched hole in the PDMS side of
the device (1 mm diameter). The device was then placed on
an inverted fluorescence microscope (Leica, Wetzlar, Ger-
many) equipped with fluorescence filters (I3, Leica Micro-
systems, Wetzlar, Germany; λex 450–490 nm, λem ≥ 515 nm)
and a Hg lamp. The set-up, containing all pumps, tubing
and the micromixer, was placed on the stage of an inverted
fluorescence microscope, located in a custom-built incubator
kept at 37 °C. The syringe containing artificial saliva (1.6 μL
min−1) was used throughout this experiment; the syringe
containing the substrate solution (0.4 μL min−1) was ex-
changed after each experimental step, so as to gradually in-
crease substrate concentration. These flow rates were used to
maintain a 4 : 1 mixing ratio of saliva with samples, as indi-
cated in Fig. 1. First, a syringe containing no substrate was
connected, as a no-substrate control, and after flow stabiliza-
tion for at least 1 min, fluorescence micrographs were taken
at the Y-junction and after each cycle of grooves. Since the
internal volume of the channel is 1.38 μL, the two solutions
to be mixed have 41.3 s to mix at an overall flow rate of 2.0
μL min−1. Fluorescence micrographs (1.0 s exposure time per
micrograph) were taken along the 51.5-mm-long channel,
thus monitoring the reaction from the exact start up to 41.3
s. For measurements at each new substrate concentration,
the syringe containing the substrate solution was exchanged,
and steps were repeated to obtain new fluorescence micro-
graphs after each cycle of grooves. The fluorescence intensity
was measured using ImageJ software (NIH, Bethesda, MD,
USA),36 calculating the 8-bit average gray value in a 300 × 100
μm rectangle drawn across the channel in each photo. The
fluorescence observed in the channel increased after each
consecutive cycle. The corresponding rate of product forma-
tion, dP/dt, was calculated by linear regression through the
initial three data points (see ESI† Fig. S5) for curves obtained
at each [S]. These initial reaction rates were then plotted ver-
sus the substrate concentration. Note that this method only
allows for calculation of dP/dt in terms of fluorescence inten-
sity. The constant required to convert measured fluorescence
to actual moles of product per time per unit of enzyme re-
mains unknown, but was not required for this initial proof-
of-concept study.
Enzymatic assays: kinetics of pepsin (protease) in the sec-
ond stage (‘stomach’). In general, the same procedure as
for the first compartment was used, with the following
modifications. The substrate used was quenched, fluores-
cently labeled casein (EnzChek Protease Green,
ThermoFisher, Waltham, MA, USA). This was dissolved at
different concentrations in fresh mineral-only artificial sa-
liva (i.e. saliva prepared in the same optimized composi-
tion, but omitting any enzymatic content) and water
(4 : 1), to represent the dilution due to mixing in the first
stage. Artificial gastric juice, containing 0.7 FIP-U mL−1
pepsin, was prepared fresh, and all solutions were heated
to 37 °C before the experiments. As for the mouth, the
set-up, containing all pumps, tubing and the micromixer,
was placed on the stage of an inverted fluorescence
microscope, located in a custom-built incubator kept at
37 °C. To maintain a 5 : 8 mixing ratio of mouth output:
gastric juice at a total flow rate of 2.0 μL min−1, artificial
gastric juice was infused at a rate of 1.23 μL min−1 (i.e.
8/13 × 2.0 μL min−1), and the various substrate solutions
were infused at a rate of 0.77 μL min−1 (i.e. 5/13 × 2.0
μL min−1), yielding a total flow rate of 2.0 μL min−1. By
using these ratios (5 : 8) between oral output (containing
the substrate) and gastric juice, we ensure that the final
gastric mixture has the same mineral composition as in
our final digestion model. The same procedure as de-
scribed for the first stage was used to obtain fluores-
cence micrographs along the channel and prepare kinet-
ics plots. Initial rates were calculated from the first five
data points.
Enzymatic assays: kinetics of proteases in the third stage
(‘intestine’). The same procedure was used as for the sec-
ond compartment, using the same substrate, quenched,
fluorescently labeled casein, but now dissolved in a mineral
mixture (1 : 4 : 8) of water, saliva and gastric juice, omitting
all enzymatic content, to represent the output of the second
compartment. To maintain a 13 : 12 mixing ratio of stom-
ach output : duodenal juices at a total flow rate of 2.0 μL
min−1, the stomach mixture was infused at a rate of 1.04
μL min−1 (i.e. 13/25 × 2.0 μL min−1), and a freshly prepared
mixture of 8 : 4 duodenal juice and bile containing 0.7 FIP-
U mL−1 proteases was infused at a rate of 0.96 μL min−1
(i.e. 12/25 × 2.0 μL min−1). The same procedure as de-
scribed for the first and second stages was used to obtain
fluorescence micrographs and prepare kinetics plots. Initial
reaction rates were calculated from the first five data
points.
Proof of concept: lactoferrin digestion
Three microreactors were connected in series, as shown in
Fig. 3. For these experiments, syringe pumps were replaced
with a flow control system based on Bronkhorst Coriolis
flow sensors.37 Bovine lactoferrin (50 mg mL−1 in ultrapure
water, Vivinal Lactoferrin, courtesy of FrieslandCampina,
Wageningen, the Netherlands), an iron-containing protein
naturally occurring in bovine milk, was continuously intro-
duced to the mouth and mixed with artificial saliva; the
resulting solution was introduced to the stomach and mixed
with gastric juice; and the resulting mixture was then intro-
duced to the intestine and mixed with duodenal juice and
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bile, at the flow rate ratios depicted in Fig. 1. Loops of con-
nective tubing were used to incubate mixtures after each
mixing stage: a 2 cm (2 min) piece of tubing after the oral
phase; a 312 cm (120 min) piece of tubing after the gastric
phase; and a 600 cm (120 min) long piece of tubing after
the intestinal phase (Fig. 3). The incubation loops of the
gastric and intestinal phases were pre-cut at places corre-
sponding to 5, 10, 30, and 60 min of incubation time to fa-
cilitate the collection of samples at these time points (see
ESI† Fig. S4). The system was operated for more than 4 h to
establish stable flows throughout the system. Samples were
then collected starting from the last time point of the intes-
tinal phase, working upstream towards the mouth. The sam-
ples were immediately diluted to 1 mg mL−1 lactoferrin,
mixed with loading buffer containing lithium dodecyl sul-
fate (NuPAGE LDS Sample Buffer 4×, Invitrogen, Carlsbad,
CA, USA) and stored at −20 °C to stop all enzymatic reac-
tions. A batch-wise in vitro digestion of lactoferrin was done
as a control experiment: a test tube containing 0.5 mL of
lactoferrin (50 mg mL−1 in ultrapure water) was mounted on
a rotary mixer (rotating head-over-heels, 24 rpm, in a 37 °C
incubator), and 2 mL of artificial saliva was added. After 2
min, 4 mL of gastric juice was added and the mixture was
incubated for 120 min. This was followed by the addition of
4 mL of duodenal juice and 2 mL of bile, and the mixture
was incubated for another 120 min. Samples were collected
from this test tube at the same time points as the micro-
fluidic digestion and were processed in a similar way. The
proteins in these samples (from both the microfluidic device
and the test tube) were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), separating
proteins and fragments thereof by size (4–12% Bis-Tris gels,
sample denaturation for 5 min at 90 °C, 5 μL sample per
well, run at 200 V for 30 min in 1× MES buffer, stained with
Expedeon Coomassie Instant Blue).
Results and discussion
In order to be able to miniaturize an in vitro digestive system
for ingested compounds, we first optimized the composition
of artificial digestive juices. This ensured that only minimal
precipitation and gas formation would occur inside our
microfluidic channels. We then verified enzyme activity in all
three compartments separately, and finally tested our
continuous-flow microfluidic digestive system using
lactoferrin, a milk protein, as a model compound.
Optimization of juice composition
Artificial mixtures resembling saliva, gastric juice, duodenal
juice and bile were initially prepared according to recipes
reported in the literature by Walczak et al.27 It was found,
however, in both off- and on-chip mixing experiments, that a
precipitate was formed in the third (intestinal) stage upon
mixing the output of the stomach (pH 1.38) with the solution
containing duodenal juice and bile (pH 8.82 and 9.03)
(Fig. 4). To understand the source of this precipitation, the
pH of the solutions corresponding to the mouth, stomach
and intestine was both calculated and determined experi-
mentally (see ESI† Table S1–3). In Table 2, the main species
that determine the pH are listed. The pH should be around
6.8 for saliva, around 1.3 for gastric juice, and around 8.1
and 8.2 for duodenal juice and bile, respectively.27 After
mixing, this should yield a pH of 1.0–2.0 in the stomach
phase and 5.5–6.5 in the intestinal phase. We calculated and
measured correct values for the mixture in the stomach using
these juices, but the mixture in the intestine was found to be
too acidic, with both the calculated and measured values be-
tween 2.0–3.0. Physiologically, the pH in the small intestine
varies, but is mostly reported as being between 7.0–8.0 after
neutralization of gastric juice by bicarbonate in the duodenal
(pancreatic) juice.1 A correct pH in each compartment will
ensure optimal enzyme function in each compartment, as
this strongly depends on pH. Moreover, protein solubilities
may be lowered at non-optimal pH. To optimize the pH of
the juices, the same concentrations of components were
used, and only the concentration of species determining the
pH were modified (see ESI† Table S3) to obtain pH values of
7.0, 3.0 and 7.0 after each successive phase. These pH values
Fig. 3 Photograph of the three micromixers, coupled in series, for the
digestion of lactoferrin. The arrows represent the flow direction in
each of the modules (red: mouth; yellow: stomach; green: intestine).
Loops of tubing of 2, 312 and 600 cm were used for incubation after
each stage, corresponding to 2, 120 and 120 min incubation time. All
inlet tubings have been removed for clarity.
Fig. 4 Precipitation and gas formation are visible at the start of the
intestinal compartment when mixing non-optimized digestive juices
(top inlet: 5 μM fluorescein, dissolved in a 1 : 4 : 8 mixture of water, sa-
liva and gastric juice; bottom inlet: an 8 : 4 mixture of duodenal juice
and bile). Red arrows indicate gas bubbles, most likely CO2. After opti-
mization of juice compositions, no precipitation was visible (see Fig. 5).
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are based on a similar, standardized, in vitro digestion proto-
col named ‘Infogest’, reported by Minekus et al.25 A pH of 3.0
in the stomach was chosen in this study based on the same
principle: the pH inside the stomach varies in vivo, at ∼2.0
when fasting but rising upon the ingestion of food,
depending on the buffer capacity of the food; therefore the
same static gastric pH of 3.0 was chosen for this study (as an
estimated average of the varying gastric pH). Besides these
changes in pH, two species which have no clear function in
in vitro digestions, mucin and bovine serum albumin, were
omitted from the juices. Adjusting the composition led to a
slight modification of the pH in saliva, as displayed in the
last column of Table 2. The concentration of hydrochloric
acid in gastric juice was lowered from 100 mM to 4 mM to
obtain a gastric mixture of pH 3.0. The concentration of bi-
carbonate and hydrochloric acid in duodenal juice and bile
were modified to obtain a theoretical final pH of 7.0, experi-
mentally determined to be around 7.3. After optimizing the
composition of the juices, precipitation and gas formation
were no longer apparent, and the system could be operated
with no interference for extended periods of time (Fig. 5).
To operate our miniaturized digestive system in continu-
ous flow mode, three micromixers were coupled in series and
all juices were infused at the flow rates described in Fig. 1.
The fluorescent dye, fluorescein (20 μM in ultrapure water),
was used as a sample to visualize flows inside the channels
(Fig. 5). Fluorescein is not susceptible to digestion or metabo-
lism under these conditions. We observed a rapid mixing
process in the mouth, which we have confirmed by character-
izing the mixing process (see ESI† Fig. S3) of these liquids.
This was done in the same fashion as the mixing process
for water and several organic solvents in mixers with
Table 2 Optimization of digestive juices: comparison of calculated and experimentally determined pH values of the four artificial digestive juices, and
the pH values after optimization to obtain theoretical pH values of 7.0, 3.0 and 7.0 in the mouth, stomach and intestine compartment, respectively












Measured (calculated) Measured (calculated)
Sample 1 Pure H2O 6.96 (7.00) 6.96 (7.00)
Saliva 4 H2PO4
−, OH− 5.8–7.1 6.45 (6.71) 6.75 (7.01)
Mixture in the mouth 5 All of the above 6.47 (6.71) 6.76 ( )
Gastric juice 8 HCl, H2PO4
− 0.6–3.2 1.16 (1.02) 2.57 (2.46)
Mixture in the stomach 13 All of the above 1.38 (1.24) 3.04 ( )
Duodenal juice 8 HCO3
−, HCl 7.0–7.7 8.82 (7.51) 8.32 (7.12)
Bile 4 HCO3
−, HCl 6.1–8.6 9.03 (7.76) 8.81 (7.35)
Mixture in the intestine 25 All of the above 2.53 (2.12) 7.31 ( )
Fig. 5 Micrographs of the three digestive modules, coupled in series. A microscope photograph was taken before and after each cycle of 12
grooves. Fluorescein, a fluorescent dye visible between pH 5–9, was used as a sample molecule (appearing white to grayish) and is not digested in
this system. In the upper series (mouth), the sample (20 μM fluorescein in ultrapure water) is continuously mixed with artificial saliva in a 1 : 4 ratio.
The resulting mixture is transferred to the middle module (stomach), where it is mixed with artificial gastric juice in a 5 : 8 ratio (flowing from right
to left). This mixture, in turn, is transferred to the lowest module (intestine), where it is mixed in a 13 : 12 ratio with a flow of artificial duodenal
juice and bile (pre-mixed in a 8 : 4 ratio). The final output is a flow of “chyme” at 25 μL min−1. The entire system, including all devices, syringe
pumps and tubing, was placed in a 37 °C microscope-incubator. Note that fluorescein is not visible in the stomach compartment, since the local
pH is too low; fluorescence re-appears in the intestinal compartment after neutralization of the gastric juice. The disappearance and reappearance
of fluorescence is almost simultaneous when a pH change is effected in the system, indicating that mixing is highly efficient. Note that the fluores-
cence intensity in the intestine is lower, due to dilution.
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herringbone-shaped grooves in an earlier study.31 The output
from the first (mouth) stage was transferred to the second
(stomach) stage using a short (2 cm) piece of tubing. We ob-
served that the fluorescence disappears within one cycle of
grooves upon mixing with gastric juice. This is because gas-
tric juice causes the pH to drop to 3.0, which is out of range
for the occurrence of fluorescence in fluorescein (pH 5–9). Af-
ter neutralizing with a mixture of duodenal juice and bile, in
the third (intestinal) stage, a reappearance of fluorescence is
observed. The resulting chyme has a pH of 7.3, and only min-
imal precipitation and gas formation were observed. Note
that the intensity of the fluorescence is decreased when it
reappears in the intestine, due to dilution.
Enzyme kinetics
To ascertain that the enzymes in the artificial digestive juices
are also active as catalysts, we performed studies of enzyme
kinetics to determine if we observed typical Michaelis–
Menten behavior. For each separate compartment, a fluores-
cent substrate was dissolved in the appropriate matrix (i.e.,
water, or a mixture of water and digestive juice to mimic the
output of preceding compartments) and was mixed on-chip
with a flow of digestive juice containing the enzyme in ques-
tion. Enzyme concentrations were fixed at their usual values
(Table 1), and the concentration of substrate, [S], in the other
inlet was increased in increments. For the first stage (mouth),
quenched, labeled starch was digested by the α-amylase (11.5
U mL−1) present in artificial saliva (Fig. 6A), yielding an in-
crease in fluorescence upon hydrolysis of the substrate. No
increase in fluorescence was visible when artificial saliva
without α-amylase was used (Fig. 6B, for all raw data see ESI†
Fig. S5). The reaction rates were measured on-chip: in our
micromixers, the absolute start of the reaction (t0) is continu-
ously visible at the Y-junction, where enzyme and substrate
meet. Each point downstream of the Y-junction corresponds
to a fixed time point in the progressing reaction, up to 41.3 s
at the end of the channel. In this way, we can transpose dis-
tance to time and continuously monitor a reaction from the
very start, allowing us to study initial reaction rates without
Fig. 6 Enzyme kinetics studies were performed in single micromixers, to demonstrate the enzymatic function of each juice. For experiments with
each separate stage, the digestive juice containing a fixed concentration of enzyme, [E], was introduced in one micromixer inlet, and a solution
containing a varying concentration of substrate, [S], was introduced in the other inlet. Cycle numbers count the number of cycles passed from the
Y-shaped confluence. A) Example of raw data (1 out of n = 3) showing the α-amylase-catalyzed digestion of different concentrations of labeled
starch in a chip (oral compartment); B) no reaction takes place when artificial saliva without α-amylase is used under the same conditions (raw
data). Initial reaction rates were measured (in graphs such as A and B) and plotted versus [S] (n = 3, average ± standard deviation). These Michaelis–
Menten plots show the digestion of C) labeled starch in the oral compartment, D) labeled casein by pepsin in the gastric compartment, and E) la-
beled casein by proteases in the intestinal compartment. The displayed concentrations of substrates are those of the substrate solution (before
mixing in the device). The white circles are control experiments, using the same juices but without any enzymatic content.
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missing initial data points. This is in contrast to what hap-
pens when the same reaction is monitored in a conventional
fluorimeter set-up, where there is a delay between the time to
mix reactants and starting fluorescence measurements (see
ESI† Fig. S8). We note that at the highest concentration of
starch (Fig. 6A), the fluorescence intensity reached a maxi-
mum value after 4 cycles (∼10 s). This raised the question if
the reaction had stopped because 1) all the substrate had
been completely converted or 2) the enzyme had ceased to
catalyze the reaction, due to e.g. shear flow-induced damage
in our micromixers. A series of control experiments was un-
dertaken to address this question. We performed the exact
same experiments in a 96-well plate, monitoring reactions
with a fluorimeter (ESI† Fig. S6). After 1 h, the reaction mix-
ture was transferred to chips to measure the fluorescence on-
chip, and we found similar endpoint fluorescence values
(ESI† Fig. S7), indicating that the same endpoint is reached
both on- and off-chip. Noteworthy is that the reaction on-
chip seems faster than the reaction off-chip in wells (ESI†
Fig. S8), possibly because of the highly efficient mixing pro-
cesses in the channel. In a final control experiment, we trans-
ferred the output of one micromixer (saliva and labeled
starch mixed 4 : 1) to another micromixer, to which we added
fresh α-amylase (ESI† Fig. S9). If the reaction in the first
micromixer had stopped because of enzyme damage, we
would expect an increase of fluorescence in the second
micromixer upon enzyme addition as remaining labeled
starch was consumed. We did not observe an increase, how-
ever, which supports the hypothesis that the reaction is in-
deed complete after only ∼10 s in the first mixer; and the re-
action does not stop because of enzyme inactivation, but
rather as a result of substrate depletion.
Reaction rates were measured both with (n = 3) and with-
out the enzyme, α-amylase, and a typical near-saturation
Michaelis–Menten plot was obtained in the former case
(Fig. 6C). No conversion factor is available to convert these
arbitrary units to moles substrate reacted per time per unit of
enzyme, but we can clearly observe Michaelis–Menten behav-
ior. These results confirm enzyme-catalyzed reactions in our
miniaturized digestive system.
For the second (stomach) and third (intestine) compart-
ments, quenched, labeled casein was used as a substrate for
proteases. Both the artificial gastric and duodenal juices con-
tain proteases, and their presence and activity is demon-
strated in this assay. In the same fashion as described for the
first compartment, the enzyme and substrate were injected
into the two separate inlets of the channel. An increase in
fluorescence occurred upon hydrolysis of casein into smaller
peptides, thereby indicating enzymatic activity. For gastric
juice (Fig. 6D, 0.7 FIP-U mL−1 pepsin), a typical Michaelis–
Menten plot was obtained, showing near-saturation at high
[S]. In the third compartment (Fig. 6E, 0.7 FIP-U mL−1 prote-
ase in the 8 : 4 mixture of duodenal juice and bile), a similar
kinetics plot was recorded, with clear saturation at high [S]
values (for raw data, see ESI† Fig. S10 and S11). The
Michaelis–Menten behavior is evident, and we have
ascertained the activity of these enzymes in our system by
digesting fluorescent model nutrients on-chip.
Lactoferrin digestion
A milk protein, lactoferrin, was dissolved in water (50 mg
mL−1) and continuously digested in our three-compartment
miniaturized digestive system as a model compound. A piece
of tubing was connected to the outlet of each compartment
to incubate the mixture of that compartment to allow for con-
tinued enzymatic action (Fig. 3). Samples were collected at
different time points in these loops and analyzed by SDS-
PAGE to assess digestion progress. Since SDS-PAGE separates
proteins and peptides by size, it yields information about the
digestion of lactoferrin, a 78 kDa protein, to smaller peptides
(Fig. 7A). In the oral phase, no digestion of lactoferrin is visi-
ble. In the gastric phase, however, we see a rapid decrease in
the intensity of the lactoferrin band (78 kDa), and bands cor-
responding to smaller peptides appear at the bottom of the
gel. From 60 min in the gastric phase on, the lactoferrin
band is no longer visible. In the intestinal phase, only a faint
band around 50 kDa can be seen, which likely originates
from lipase in the artificial duodenal juice. The same diges-
tion was carried out in a test tube rotating head-over-heels, as
a control experiment under the same conditions (Fig. 7B).
There, we observe a slower digestion in the gastric phase,
with the lactoferrin band (around 78 kDa) becoming less
Fig. 7 SDS-PAGE gels showing results of the digestion of lactoferrin
(50 mg mL−1 in water) in A) our microfluidic digestive system and B) a
test tube rotating head-over-heels. The same artificial digestive juices
were used for both experiments, and both were carried out in
incubators set at 37 °C. All samples were diluted to 1 mg mL−1
lactoferrin before analysis (marker protein size displayed in kDa). LF:
lactoferrin control sample; O-2: oral phase sample after 2 min; G-5:
gastric phase sample after 5 min, etc.; I-5: intestinal phase sample after
5 min, etc.
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intense over time, but not disappearing. After transferring
the mixture to the intestinal phase, the lactoferrin band
disappeared within 5 min by rapid protease activity of the du-
odenal juice. The digestion of lactoferrin was therefore faster
in our miniaturized system, as compared to a rotating test
tube. We hypothesize that most of the digestive action takes
place in the micromixer of the stomach, even though it only
has a residence time of 6 s: the output of the oral phase and
gastric juice are thoroughly mixed by the folding-like motions
of the liquid in the micromixer, causing a fully mixed gastric
mixture after only a few cycles. Digested lactoferrin fragments
are visible at the bottom of the gel. The digestive enzymes,
α-amylase and pepsin, will also be digested, but because of
their low abundance, they are not visible in these gels. Even
after 120 min in the gastric phase, the lactoferrin fragments
are not fully digested. After transferring to the intestine, how-
ever, these bands <10 kDa quickly disappear, indicating com-
plete digestion. The digestion of lactoferrin occurs partly in
the stomach and partly in the intestine, and is therefore a
good example to show multi-compartment digestion in our
system.
Conclusion and future outlook
We have described the development of a three-compartment,
microfluidic digestion system, in which we can vary the reac-
tion conditions from one compartment to the next, allowing
different reactions to take place. We have demonstrated enzy-
matic function by digesting fluorescent compounds and by
digesting molecules which are of interest in the field of nutri-
tion. As shown for the milk protein, lactoferrin, the digestion
in our miniaturized system is considerably faster than batch-
wise digestions in vitro, and will save time as well as
chemicals (with a combined net consumption of 6 mL of di-
gestive juices per 4 h digestion, at 25 μL min−1). We expect
that our system will need a shorter timespan for digestion
than in the physiological situation, due to fast and thorough
mixing. Digestion times in our model system need to be com-
pared to physiological conditions in order to further optimize
incubation times. In the future, this system will be coupled
to a gut-on-a-chip, a barrier model of the human intestine
containing living epithelium. This would allow integrated
testing of the terms FF and FG, related to compound bioavail-
ability, for new drugs, toxicants and nutrients. When coupled
in-line to a device mimicking the human liver (e.g. a liver-on-
a-chip), the full bioavailability F (including FF, FG and FH)
could be studied, by transferring the basolateral flow of the
gut-on-a-chip via a ‘portal vein’ connection to a piece of liver
tissue. We will be investigating the in-line conjugation to a
gut-on-a-chip next, to study the uptake of medicinal drugs
and toxicants after digestion.
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